B. Wenrich

Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.

W. Rumsey, B. Undem, P. Bernstein, 2001, The Journal of pharmacology and experimental therapeutics.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

P. Adamson, F. Balis, B. Widemann, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.